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Summary
 
Bovine 
 
g
 
/
 
d
 
 T cells and neutrophils roll on 24 h cytokine- or lipopolysaccharide-stimulated bo-
vine fetal umbilical cord endothelial cells in assays done under physiological flow. An antibody
directed against E- and L-selectin has minimal blocking effect on this rolling interaction. mAbs
were raised against the stimulated bovine endothelial cells and screened for inhibition of 
 
g
 
/
 
d
 
 T
cell rolling. One mAb (GR113) was identified that recognizes an antigen (GR antigen) selec-
tively expressed by stimulated bovine endothelial cells isolated from fetal umbilical cord, mes-
enteric lymph nodes, and aorta. GR113 blocked bovine 
 
g
 
/
 
d
 
 T cell as well as neutrophil rolling
on the 24 h-activated endothelial cells. The GR antigen was constitutively expressed at low
levels on the cell surface of platelets and its expression was not upregulated after stimulation of
these cells with thrombin or phorbol myristate acetate. However, stimulated platelets released a
soluble, functionally active form of the molecule that selectively bound in solution to 
 
g
 
/
 
d
 
 T
cells in a mixed lymphocyte preparation. GR113 mAb blocked the binding of the soluble
platelet molecule to the 
 
g
 
/
 
d
 
 T cells. Soluble GR antigen also bound a subset of human lym-
phocytes. Cutaneous lymphocyte-associated antigen (CLA) bright human lymphocytes exhib-
ited the greatest capacity to bind the GR antigen, though CLA was not required for binding.
Subsets of both human CD4 and CD8 T cells bound the GR antigen. Immunoprecipitation
experiments showed the GR antigen to be 110-120 kD 
 
M
 
r
 
. The binding of soluble GR anti-
gen was inhibited by EDTA and 
 
O
 
-sialoglycoprotease, but not neuraminidase treatment of the
target cells.
 
L
 
eukocyte recruitment into sites of inflammation in-
volves a multi-step process that leads to the accumula-
tion of cells from the blood into the underlying inflamed
tissue (1–5). Endothelial cells lining venules in sites of in-
flammation respond to inflammatory mediators, which leads
to expression of adhesion molecules on their cell surface.
Leukocytes within the flow of blood recognize the newly
expressed adhesion molecules, bind and begin to roll along
the vessel wall. Eventually, many of the rolling leukocytes
tightly adhere to the endothelial cell lining, and migrate
into the underlying tissue (1–5).
Most leukocyte rolling interactions are mediated by a
family of adhesion proteins called selectins and their diverse
ligands, though important exceptions exist. To date, three
selectins have been defined: E-selectin on inflamed endo-
thelial cells; P-selectin on activated platelets and endothelial
cells; and L-selectin on circulating leukocytes (2). Antibod-
ies against each of the selectins can block leukocyte rolling
under various conditions in vitro and in vivo (6–19). Other
molecules that can mediate rolling include the integrins,
 
a
 
4/
 
b
 
1 and 
 
a
 
4/
 
b
 
7 on mononuclear cells, and vascular cell
adhesion molecule-1 (VCAM-1)
 
1
 
 and mucosal addressin
cell adhesion molecule-1 (MAdCAM-1) on endothelial cells
(15, 19, 20–22). Though antibodies against selectins and
their ligands and integrins and their ligands block most roll-
ing interactions that have been defined in vitro, a recent re-
port suggests that 24 h cytokine stimulation of cultured hu-
man endothelial cells leads to leukocyte rolling that does
not involve any of the known adhesion systems (23). The
rolling interaction exhibits the characteristics of a selectin-
like event, yet it is distinct from E-, P-, and L-selectin (23).
Recently, we have characterized the interaction of bo-
vine 
 
g
 
/
 
d
 
 T cells with acutely inflamed (
 
,
 
6 h) endothelium
in vitro and defined a prominent role for selectins in medi-
ating the rolling of these cells under physiological flow (12,
24, 25). Here, we found that 24-h stimulation (LPS or cy-
 
1
 
Abbreviations used in this paper:
 
 BUVECs, bovine umbilical vein endothe-
lial cells; CLA, cutaneous lymphocyte-associated antigen; MAdCAM-1,
mucosal addressin cell adhesion molecule-1; PSGL-1, P-selectin glyco-
protein ligand-1; PVDF, polyvinylidene difluoride; VCAM, vascular cell
adhesion molecule-1.
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tokine) of bovine umbilical vein endothelial cells leads to a
reproducible rolling interaction of 
 
g
 
/
 
d
 
 T cells under flow
conditions, which is not blocked by antibodies against E- or
L-selectin. A mAb (GR113) was raised against the activated
endothelial cells that blocks the rolling event. GR113 rec-
ognizes a 110–120-kD 
 
M
 
r
 
 surface antigen on cytokine-
stimulated endothelial cells. Platelets release a functionally
active form of the molecule upon stimulation, which selec-
tively binds 
 
g
 
/
 
d
 
 T cells in mixed bovine lymphocyte cell
preparations. The soluble antigen also binds human leuko-
cytes and optimal binding correlates with high expression
of the cutaneous lymphocyte-associated (CLA) E-selectin
ligand on human T cells, but CLA is not required for bind-
ing. EDTA and 
 
O
 
-sialoglycoprotease treatments block the
binding interaction. The antigen is expressed by postcapil-
lary venules in sites associated with inflammatory leuko-
cytes in a chronically inflamed tissue.
 
Materials and Methods
 
Animals.
 
BALB/c mice, ranging in age from 6–12 wk, were
used for the generation of mAbs. The mice were housed in the
small animal facility at Montana State University (Bozeman, MT).
1-wk–3-mo-old calves, which were housed in the MSU large an-
imal facility, were used as sources of peripheral blood and for in-
flamed tissues.
 
Cell Preparations.
 
Leukocytes were harvested from the pe-
ripheral blood of cattle and humans, as previously described (6, 11,
24, 25). In brief, blood was collected into citrate, EDTA or hep-
arin anticoagulant tubes, diluted 1:2 with warm HBSS, under-
layed with Histopaque 1077 (Sigma Chemical Corp., St. Louis,
MO), and centrifuged at 800 
 
g
 
 for 30 min at room temperature.
Mononuclear cells were collected from the Histopaque/plasma in-
terface. Neutrophil preparations were made by hypotonic lysis of
RBCs. Monocytes were removed from the mononuclear cell prep-
aration by adhesion to plastic and 
 
g
 
/
 
d
 
 T cells were purified by a
30-min incubation on monolayers of E-selectin cDNA-trans-
fected L-cells. After the incubation period, the 
 
g
 
/
 
d
 
 T cells were
removed from the monolayer by incubation in 2 mM EDTA.
This procedure yielded a population 
 
.
 
90% 
 
g
 
/
 
d
 
 T cells (12, 24,
25, 26). In some experiments human lymphocytes were cultured
in Ex Vivo 15 medium (BioWhittaker, Waltersville, MD), plus 5
 
m
 
g/ml Con A (5
 
 3 
 
10
 
7
 
 cells in 15 ml; Sigma) for 6 d. In others,
bovine lymphocytes were treated with a 3-d PMA-stimulated
lymphocyte supernatant fluid for 2 h at 37
 
8
 
C.
Platelets were isolated from Histopaque-separated leukocytes by
three successive low speed spins (100 
 
g
 
), which resulted in pellet-
ing of the leukocytes while the platelets remained in suspension.
The platelets were resuspended in HBSS and kept on ice until
used in the capillary tube shear assay described below or they
were used as antigen sources. Bovine umbilical vein endothelial
cells (BUVECs) or aorta derived endothelial cells were isolated by
collagenase (type 2; Worthington Biochemical Corp., Freehold,
NJ) digestion of the lumenal surface of cords or aorta, and cul-
tures were established as described previously (12, 25). Primary
endothelial cell cultures were established from stroma of mesen-
teric lymph nodes as well. In brief, mesenteric lymph nodes were
minced with a razor blade. The stromal fragments were exten-
sively washed in HBSS to remove nonadherent lymphocytes, dis-
persed with collagenase (type A1; Sigma), washed multiple times,
and then cultured in endothelial cell medium (EGM; Clonetics,
San Diego, CA) to select for endothelial cells. Colonies that grew
out from the fragments, which exhibited the distinctive cobble-
stone morphology of endothelial cells, were physically removed
from the cultures and passaged into new flasks. Only endothelial
cells from passage five or less were used in functional analyses.
The following antibodies were used in this study: GD3.8, a
mouse IgG1 that selectively stains bovine 
 
g
 
/
 
d
 
 T cells (26); HECA
452, a rat IgM that stains CLA on human leukocytes (27, 28);
EL-246, a mouse IgG1 that stains bovine L- and E-selectin (29);
and rabbit polyclonal anti-sera specific for bovine P-selectin and
E-selectin (30–33). Preimmune rabbit serum, irrelevant isotype-
matched mAbs, or second stage reagents were used as negative
controls.
Bovine thrombin (Sigma), PMA (Sigma), Cell Tak (Collabora-
tive Biomedical Products, Bedford, MA), neuraminidase (Calbio-
chem Novabiochem Inc., San Diego, CA), LPS (from 
 
Serratia
marcescens
 
; Sigma) and 
 
O
 
-sialoglycoprotease from 
 
Pastuerella haemo-
lytica
 
 (Pierce Chemicals Inc., Rockford, IL) were used. Pig TNF-
 
a
 
,
which crossreacts in cattle, was purchased from Endogen, Inc.
(Boston, MA). Mouse IFN-
 
g
 
 was a gift of E. Amento while at
Genentech, Inc. (South San Francisco, CA).
 
Capillary Tube Shear-dependent Rolling Assay.
 
We and others
have previously described an approach for measuring the interac-
tion of leukocytes with cells expressing adhesion molecules under
controlled shear forces (6, 11, 12, 20, 25, 34). For the functional
studies described here, mouse IFN-
 
g
 
 (1
 
 3 
 
10
 
4
 
 U/ml for 24 h)/
TNF-
 
a
 
 (500 ng/ml, 5–6 h)-stimulated BUVECs were grown on
the internal surface of sterile glass 1.4-mm capillary tubes (Drum-
mond Scientific, Broomall, Penn) (12, 25). Endothelial cells (1
 
 3
 
10
 
5
 
) were seeded into the tubes and cultured for 24 h, which
consistently resulted in a confluent monolayer. Tubing (internal
diameter of 1.5 mm) was attached to each end of the capillary
tube to form a closed system in which fluid and cells could be re-
circulated using a variable peristaltic pump (Cole Parmer, Bar-
rington, IL) containing 6 rollers to reduce pulsation. The capillary
tube was mounted on an inverted microscope (Nikon Diaphot)
modified for video microscopy (Sony CCD Camera). Purified 
 
g
 
/
 
d
 
T cells or neutrophils were injected into the system at 4
 
 3 
 
10
 
6
 
cells/ml in DMEM plus 20 mM Hepes. A reproducible rolling
interaction on the cytokine-activated endothelial cells was de-
tected under a shear force of 
 
z
 
2 dynes/cm
 
2 
 
(20). The number of
rolling 
 
g
 
/
 
d
 
 T cells on cytokine-stimulated endothelial cells, and
in the assays below, at 60-s intervals was determined by analysis of
individual frames of the videotape recording using macro-driven
NIH Image software and a Macintosh 660 AV computer (Apple,
Cupertino, CA). Data were recorded as the number of rolling cells
within the field of view versus time. Aggregates were excluded
from the analyses.
For P-selectin assays, platelets isolated from bovine plasma were
activated with 1
 
 m
 
g/ml bovine thrombin and coated at 1.5
 
 3 
 
10
 
9
 
cells/ml onto the internal surface of Cell Tak-coated capillary
tubes, and allowed to attach for 15–30 min. Shear assays were
then performed, as previously described (12). In brief, bovine 
 
g
 
/
 
d
 
T cells were injected at 4
 
 3 
 
10
 
6
 
 cells/ml in DMEM plus 20 mM
Hepes. The interaction of the leukocytes with the bound platelets
was monitored by video microscopy at 2 dynes/cm
 
2
 
, as described
above.
 
Generation of mAbs that Selectively Stain Cytokine-stimulated En-
dothelial Cells.
 
Bovine endothelial cells stimulated for 24 h with
IFN-
 
g
 
 (1
 
 3 
 
10
 
4
 
/ml) followed by TNF-
 
a
 
 (500 ng/ml) or LPS (1
 
m
 
g/ml) for 4-6 h, which avidly supported 
 
g
 
/
 
d
 
 T cell rolling un-
der flow conditions, were used to immunize mice (5
 
 3 
 
10
 
7
 
-1
 
 3
 
10
 
8
 
 cells) until significant titers (
 
.
 
1:1,000) of serum antibodies 
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were generated that selectively stained the cytokine-stimulated en-
dothelial cells and blocked the rolling of the 
 
g
 
/
 
d
 
 T cells. Fusions
were done, as previously described (26, 29, 35), and the superna-
tant fluids from the hybridoma cells were screened on control
versus cytokine-activated endothelial cells using an ELISA-based
screening assay. In brief, endothelial cells were grown in the wells
of a 96-well plate and some were stimulated with IFN-
 
g
 
 for 24 h
followed by a 5-h treatment with TNF-
 
a
 
 or LPS, as described
above, whereas others were left untreated. Hybridoma supernatant
fluids were added to PBS washed wells and allowed to incubate at
37
 
8
 
C for 30 min. The wells were washed in PBS and then treated
with 1% paraformaldehyde for 30 min at room temperature. The
plates were washed again in PBS and second stage anti–mouse Ig
coupled to biotin (Biosource, Inc., Camarillo, CA) was added and
incubated for 30 min at room temperature. The plates were
washed and streptavidin-peroxidase (Biosource, Inc.) was added,
incubated for 20 min at room temperature, and developed by the
addition of AEC substrate (Sigma). Hybridomas that produced
antibodies, which selectively stained the cytokine-stimulated en-
dothelial cells, were expanded and subcloned by limiting dilution.
One mAb, GR113 (mouse IgG1), was characterized in this re-
port.
 
Soluble Platelet Antigen Binding Assay.
 
Isolated platelets from
150 ml of blood were resuspended in 10 ml of RPMI and stimu-
lated with thrombin (1
 
 m
 
g/ml) or PMA (100 ng/ml) for 2 h at
37
 
8
 
C. The platelets were removed by high-speed centrifugation
(800 
 
g
 
) and the clarified supernatant fluid collected. Bovine or
human leukocytes were incubated with the platelet supernatant
fluid with or without various activating agents at 37
 
8
 
C for 1.5 h at
37
 
8
 
C. After the incubation period, the treated leukocytes were
washed and then stained for flow cytometric analysis to detect
bound GR antigen and to determine the phenotype of the bind-
ing population. For two-color analysis after the binding assay, cells
were first stained with GR113 followed by anti-mouse Ig-PE in
one color. The cells were then washed, incubated in 10% mouse
serum to block free sites on the second stage, and then stained
with FITC-labeled HECA452 (anti-CLA), anti-CD4 (Becton Dick-
inson, San Jose, CA), or anti-CD45RO (Becton Dickinson) for
human cells, or FITC-labeled GD3.8 (anti-bovine 
 
g
 
/
 
d
 
 T cells) for
bovine cells. Specificity controls included treating the platelet su-
pernatant fluid with blocking GR113 and nonblocking isotype
matched mAbs and EDTA. Neuraminidase and 
 
O
 
-sialoglycopro-
tease treatments of the leukocytes before the binding assays were
also done. EDTA was used at a 2 mM concentration. Neuramini-
dase (0.1
 
 m
 
g/ml) and 
 
O
 
-sialoglycoprotease (50
 
 m
 
g/ml) were used
to treat the leukocyte preparations for 30–45 min at 37
 
8
 
C or room
temperature before the binding assay, as described (23–25). Rele-
vant buffers were used as controls for the treatments. The cells
were analyzed on a Becton Dickinson FACScan
 
Ò
 
 or FACSCali-
bur
 
Ò
 
 
 
(San Jose, CA).
 
SDS-PAGE/Western Blot and Immunoprecipitation Procedures.
 
Isolated platelets were lysed in a 1% Triton X-100 detergent buf-
fer containing 0.005% SDS, 1 mM EDTA, PBS and protease in-
hibitors at 4
 
8
 
C for 60 min. Cell debris was removed by centrifu-
gation (microfuge) and then the lysate was run on an 8% PAGE
gel under reducing or nonreducing conditions. In some experi-
ments, GR113 mAb was covalently attached to cyanogen bromide-
activated Sepharose beads, per manufacturer’s recommendations
(Pharmacia LKB Inc., Piscataway, NJ), and used to affinity purify
the GR113 antigen. The purified antigen was then run on an 8%
SDS-PAGE gel. The separated platelet proteins were transferred
to nitrocellulose overnight and then the nitrocellulose blot was
blocked with horse serum for 30 min. The nitrocellulose was then
blotted with GR113, a polyclonal anti-serum against bovine
P-selectin, or various negative control antibodies using a 24-well
miniblotter apparatus (Immunetics Inc., Cambridge, MA). After a
1-h incubation at room temperature, the blots were washed and
then second-stage alkaline phosphatase-coupled reagents specific
for either mouse Ig (Sigma) or rabbit Ig (Sigma) were added and
allowed to incubate with the blots for 1 h at room temperature.
The blots were washed extensively and then developed by the
addition of nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl
phosphate (Sigma) in AP buffer (100 mM Tris, pH 9.5, 100 mM
NaCl, and 5 mM MgCl
 
2
 
).
For the immunoprecipitation procedures, endothelial cells were
grown in T175 flasks and activated for 6 h with 1 ng/ml LPS to
get both GR antigen and E-selectin expressed. The endothelial cell
monolayers were surface labeled with biotin (10 ml of 0.55 mg/ml
immuno-pure NHS-LC-biotin sulfosuccinimidyl 6-biotinamido
heranoate [Pierce] in PBS) for 30 min at room temperature. The
monolayers were washed, physically removed from the flasks us-
ing a cell scrapper, and washed three additional times in PBS to
remove all residual biotin. The endothelial cells were lysed in the
Triton X-100 lysis buffer, as described above. The biotin-labeled
lysate was divided into two fractions and precleared with either
5% rabbit serum or 5% mouse serum followed by protein–A aga-
rose (Sigma) or protein–G agarose (Boehringer Mannheim, Indi-
anapolis, IN), respectively, for 4–5 h at 4
 
8
 
C. The protein A and
protein G beads were removed by centrifugation and the proce-
dure repeated a second time. The precleared lysates were then
immunoprecipitated with GR113 (lysate precleared with mouse
serum) or rabbit polyclonal antiserum against either E-or P-selec-
tin (lysate precleared with rabbit serum), as previously described
(26). The immunoprecipitated samples were resuspended in non-
reducing SDS-sample buffer and run on an 8% PAGE-gel. After
the electrophoresis step, the gels were transferred to polyvi-
nylidene difluoride (PVDF) membrane overnight and then the
PVDF membrane was blocked in a 7% BSA NaCl buffer for 2 h
at room temperature. The blot was washed and then incubated
for 30 min with streptavidin-horseradish peroxidase conjugate
(Amersham, Inc., Arlington Heights, IL) diluted 1:5,000 in PBS,
followed by development with ECL chemiluminescent detection
reagents from Amersham.
Chronic Inflammation Lesions. To induce a chronic inflamma-
tory lesion, plastic golf ball–sized wiffle balls were inserted under
the skin of young calves. The balls were allowed to be encapsu-
lated and then were injected with 1 ml of a 1:20 dilution of a sat-
urated potassium permanganate preparation. The resulting in-
flammatory response was allowed to continue until the tissue
within the ball became solid, as detected by X-irradiation and auto-
radiography. The wiffle ball was removed and the inflammatory
tissue cut and frozen in O.C.T. freezing medium (Tissue-Tek, Inc.,
Elkhart, IN). To induce acute inflammatory lesions, LPS was injected
into the dermis and tissue samples were collected 4–6 h later. For
immunohistology, frozen sections were allowed to air dry, fixed
in acetone, and then stained for immunohistology, as previously
described (24).
Results
GR113 Selectively Stains Cytokine- or LPS-stimulated En-
dothelial Cells and Blocks Their Capacity to Support g/d T Cell
and Neutrophil Rolling under Physiological Flow. Endothelial
cells stimulated for 24 h with IFN-g followed by LPS or
TNF-a for 4–6 h avidly supported g/d T cell rolling under1704 Leukocyte Rolling on 24 h-stimulated Endothelial Cells
flow conditions; however, the rolling interaction was not
blocked by an antibody directed against L- and E-selectin
(EL-246) (Fig. 1 A). Similar rolling interactions occurred
on endothelial cells treated with LPS or TNF-a alone for
24 h, showing that the IFN-g pretreatment was not prerequi-
site, but the consistency of the induction of the capacity
support rolling was enhanced by IFN-g (data not shown).
mAbs were raised against the 24 h cytokine-stimulated
endothelial cells, as described in Materials and Methods. One
mAb, GR113, was identified that selectively stained endo-
thelial cells treated for 24 h. Untreated umbilical cord en-
dothelial cells expressed little if any GR antigen on their
cell surface or in intracellular pools (data not shown, also see
Fig. 2). In one experiment, the expression of the GR anti-
gen was compared with E-selectin after 6 and 24 h LPS treat-
ment of endothelial cells isolated from mesenteric lymph
nodes, aorta, and fetal umbilical cords. As shown in Fig. 2,
GR113 selectively stained LPS-stimulated endothelial cells
isolated from all three sources. 6 h stimulation with LPS (or
TNF-a, data not shown) alone led to increased staining of
endothelial cells in all three cases and, for the most part,
maximal or close to maximal expression was maintained af-
ter 24 h (Fig. 2). In contrast, induction of E-selectin ex-
pression was highly variable, with endothelial cells from
umbilical cords expressing significant antigen before stimu-
lation; whereas little E-selectin was expressed on endothe-
lial cells from mesenteric lymph nodes after either 6 or 24 h
incubation in the presence of LPS (Fig. 2). The reason for
the variability in E-selectin expression or the consistency of
this variability was not determined, but it could have been
related to the proliferative state of the cells (33). Flow cyto-
metric analysis showed that virtually all 24 h stimulated
umbilical cord endothelial cells expressed the GR antigen,
though there was heterogeneity in the level of expression
by different cells in the culture (Fig. 3). Overall, we have
shown that TNF-a, LPS, or a combination of IFN-g plus
LPS or TNF-a, but not IFN-g alone, induced significant
levels of the GR antigen on bovine endothelial cells (data
not shown). Since much of our initial analyses were on
umbilical cord endothelial cells pretreated with IFN-g for
24 h followed by LPS or TNF-a treatment, this treatment
regime was used in the functional analyses reported below.
GR113 was tested in the capillary tube shear assay for its
ability to block g/d T cell rolling on the 24 h stimulated um-
bilical cord endothelial cells. In the first series of experiments,
rolling interactions were established, a negative control an-
Figure 1. GR113 blocks g/d T cell and neutrophil rolling on 24 h cy-
tokine-activated endothelial cells. Endothelial cells were grown on the in-
ternal surface of glass capillary tubes, activated with IFN-g/TNF-a, and
integrated into the flow assay, as described in Materials and Methods. In
A, g/d T cell rolling was established first and then an isotype-matched
negative control mAb (control), EL-246 (anti–L- and E-selectin), and
GR113 were sequentially added. In B, the endothelial cell monolayer was
either pretreated with GR113 or a control mAb for 30 min before the ad-
dition of the g/d T cells. In C, the rolling of neutrophils on endothelial
cells pretreated with GR113 was compared with antibody control. These
experiments are representative of .3 other experiments showing inhibi-
tion of leukocyte rolling on the 24 h cytokine- or LPS-activated endothe-
lial cells.
Figure 2. GR113 stains 6 h and 24 h LPS-stimulated endothelial cells
isolated from mesenteric lymph nodes, aorta, and umbilical cords. Endo-
thelial cell cultures in 96 well plates were stimulated with LPS for 6 and 24 h
and then stained with GR113 (denoted GR antigen) or EL-246 (anti–
E-selectin, denoted ES antigen), as described in Materials and Methods.
The data represent a single comparison and are the average of duplicate
measurements. OD values reflect OD of positive staining mAb minus OD
of negative control antibody staining. The staining of the umbilical cord
endothelial cells which were used in all subsequent assays was repeated in
.3 different experiments.1705 Jutila et al.
tibody injected, which was then followed sequentially by
EL-246 (anti–L- and E-selectin), which had no effect, and
GR113, which almost completely blocked the rolling inter-
action within 1 min (Fig. 1 A). As shown in Fig. 1 B, pre-
treatment of endothelial cells completely prevented their abil-
ity to support g/d T cell rolling. As seen in the studies
using human endothelial cells (23), neutrophils rolled on the
24 h stimulated endothelial cells, though not nearly as well
as the lymphocytes (compare the number of rolling cells). Pre-
treatment of the endothelial cells with GR113 completely
blocked the neutrophil rolling interaction (Fig. 1 C). 
Distribution of the GR Antigen. Since GR113 selectively
stained cytokine-stimulated endothelial cells in vitro, the
staining pattern in chronic inflammatory lesions in vivo was
tested. As shown in Fig. 4 A, GR113 intensely stained ves-
sels associated with leukocytes in a chronic inflammatory
lesion induced by potassium permanganate. Upon closer
examination of the GR113 positive vessels it was noted
that not only did the antibody stain endothelial cells, scat-
tered granular platelet-like particles (also see below) were
also stained (Fig. 4 B). Note in Fig. 4 B that leukocytes
were adhered to the lumenal surface of the large GR113
positive vessel. We detected variable, low level of staining
of GR113 on vessels in uninflamed skin. 4 h LPS-inflamed
skin exhibited positive vessels, but much of the staining was
associated with platelet-like particles. In contrast, E-selectin
was expressed on many vessels in the 4 h inflamed tissues,
whereas minimal expression was seen in the chronic lesion
(data not shown).
Flow cytometric analysis was done to determine if
GR113 reacted with any blood cells, particularly platelets.
As shown in Fig. 5 A, the antibody weakly stained platelets
by flow cytometric analysis. In some experiments, reactiv-
ity of GR113 on platelets was barely above background
(data not shown). As shown in Fig. 5 A, thrombin activa-
tion did not lead to increased GR113 staining. The throm-
bin-activated platelets supported avid rolling of bovine g/d
T cells in the capillary tube flow assay, suggesting that they
did express P-selectin; however, GR113 did not block the
interaction (Fig. 5 B), as seen with g/d T cell rolling on 24 h
cytokine-stimulated endothelial cells (Fig. 1). 
GR Antigen Is Released in a Functional Form by Activated
Platelets. A series of activation experiments were initially
done to determine if the GR antigen could be induced on
the surface of blood leukocytes. Treatment of a mixed pop-
ulation of mononuclear cells, containing lymphocytes, mono-
cytes, and platelets, with PMA or an activated lymphocyte
Figure 3. GR113 stains 24 hour LPS-stimulated umbilical cord endo-
thelial cells as measured by flow cytometric analysis. Stimulated endothe-
lial cells were lifted by incubation in EDTA and physical scrapping of the
monolayers, dissociated, washed, stained with GR113 and analyzed by flow
cytometry. Solid line reflects staining with GR113 and the dotted line
represents background staining with a negative control. Expression is in
arbitrary fluorescence units on a log scale.
Figure 4. GR113 stains venules in a site of chronic inflammation. A
chronic inflammatory lesion was induced by potassium permanganate, as
described in Materials and Methods, which was characterized by an infil-
tration of mononuclear leukocytes with many of the inflammatory cells
being lymphocytes (data not shown). Frozen sections were stained with
GR113 by standard immunoperoxidase techniques. A shows a low power
(1253 final magnification) field demonstrating many GR113 positive
vessels in the site of leukocyte infiltration (arrowheads). B shows a high
power field (2503 final magnification) of the same tissue. The arrow head
points to a GR113 positive vessel containing leukocytes bound to its lu-
menal surface.1706 Leukocyte Rolling on 24 h-stimulated Endothelial Cells
supernatant fluid (3 d PMA-treated lymphocyte superna-
tant fluid shown in another study to be a potent activator of
bovine lymphocytes) led to reproducible staining of a large
percentage of g/d T cells with GR113 within two h (Fig.
6, A and B). However, if purified g/d T cells (purified by
panning on E-selectin transfectants, as described in Materi-
als and Methods, and lacking most other leukocytes and
platelets) were directly stimulated, they did not express the
GR antigen (Fig. 6, C and D).
Subsequently, it was found that platelets released the an-
tigen upon PMA or thrombin stimulation (data not shown).
To determine if the leukocyte staining shown in Fig. 6 B,
could be due to released GR antigen from contaminating
platelets, supernatant fluid from PMA or thrombin-stimu-
lated platelets (see Materials and Methods) was collected
(both worked equally well) and used to treat purified bo-
vine g/d T cells. After 1.5 h, the treated cells were washed
and stained with GR113 for flow cytometric analyses. As
shown in Fig. 6 (E and F), GR113 specifically stained the
supernatant fluid-treated g/d T cells. In mixed lymphocyte
preparations, g/d T cells were the only cell that bound the
soluble GR antigen (data not shown).
To determine the specificity of the GR antigen binding
to g/d T cells in suspension, the platelet supernatant fluid
was pretreated with the GR113 antibody before the bind-
ing assay. As shown in Fig. 7 (A and B), GR113 pretreat-
ment prevented binding of the GR antigen to the g/d T cells.
Importantly, antibodies directed against L-selectin or other
g/d T cell surface antigens had no effect on the binding of
the GR antigen (Fig. 7 and data not shown). Since the block-
ing GR113 mAb could detect bound antigen on the sur-
face of the g/d T cells, this suggested that the soluble mol-
ecule was likely aggregated, creating multiple binding sites,
some of which were unoccupied when bound to the leu-
kocyte. Binding of soluble GR antigen to leukocytes was
inhibited by EDTA (2 mM) and O-sialoglycoprotease (50
mg/ml), but not neuraminidase (0.1 U/ml) treatment of
the g/d T cells (Fig. 7). EDTA and O-sialoglycoprotease
treatment of g/d T cells also blocked their capacity to roll
on the 24 h stimulated endothelial cells (data not shown).
Soluble GR Antigen Specifically Binds a Subpopulation of
Human Lymphocytes. The GR113 antibody did not cross-
react with human cells (data not shown). To determine if
human leukocytes express receptors for the GR antigen, the
binding of soluble bovine GR antigen to human mononu-
clear cells was tested. GR antigen containing supernatant
fluid from bovine platelets was used to treat human mono-
nuclear cells. The cells were washed and then analyzed by
Figure 5. Staining of GR113 on
platelets and its effect on leukocyte roll-
ing on thrombin-activated platelets. Plate-
lets, isolated as described in Materials and
Methods, were stained with the GR113
mAb and analyzed by flow cytometry or
they were used in rolling assays. A shows
GR113 staining of control and throm-
bin-activated (15 min) platelets versus
background staining (second stage alone).
B shows the effects of GR113 on the
rolling of bovine g/d T cells on immobi-
lized, thrombin-activated platelets. Two
different experiments are shown in which
rolling interactions were established first,
and negative control (EL-246) and GR113
mAbs sequentially injected.
Figure 6. Staining of blood leukocytes with GR113. Two-color flow
cytometric analysis was done using GR113 (GR staining) versus a g/d T
cell specific mAb (GD3.8) on bovine lymphocytes treated by different
protocols. A and B shows GR113 staining of bovine peripheral blood
mononuclear cells before (A) and after (B) treatment (1.5 h) with a PMA-
induced lymphocyte supernatant fluid, which we had previously shown
in other studies to be a potent activator of bovine lymphocytes. C and D
show GR113 staining of purified g/d T cells before (C) and after (D)
treatment with the PMA-induced lymphocyte supernatant fluid. E and F
show GR113 staining of purified g/d T cells before and after treatment
with a clarified supernatant fluid from thrombin-activated platelets, as de-
scribed in Materials and Methods. The quadrants reflect the upper end of
background staining seen with negative controls. Both the y and x axis are
in log units. The results are representative of at least three other experi-
ments with similar results.1707 Jutila et al.
two-color analysis using GR113 and HECA 452 to stain the
E-selectin binding lymphocyte population (CLA) (27), as a
comparison. These analyses showed that most HECA 452
bright cells bound the GR antigen (GR antigen also bound
some HECA 452-negative cells, Fig. 8). Importantly, the
binding of the soluble GR antigen to human lymphocytes
was completely blocked by pretreatment of the platelet su-
pernatant fluid with GR113 (Fig. 8). As with bovine cells,
neuraminidase treatment had no effect on GR antigen bind-
ing, though HECA 452 reactivity was greatly reduced (data
not shown). Human monocytes and neutrophils also bound
the GR antigen and rolled on 24 h activated bovine endo-
thelial cells, which was blocked by the GR113 mAb (data
not shown).
The percentage of human lymphocytes that bound the
GR antigen varied considerably from donor to donor, mak-
ing extensive phenotypic analysis of the cells difficult. There-
fore, the binding of GR antigen to cultured human lym-
phocytes expanded in the presence of Con A was tested. As
shown in Fig. 9, after 6 d culture in Ex Vivo 15 medium
plus 5 mg/ml Con A, almost all of the lymphocytes exhib-
ited a memory phenotype as defined by expression of the
CD45RO isoform. GR antigen bound a large percentage,
but clearly not all, of the Con A–treated, CD45RO-posi-
tive lymphocytes and, again, optimal GR antigen binding
correlated with CLA expression (Fig. 9). Anti-CD4 stain-
ing was also done in this experiment, which showed that a
signficant percentage of CD4-positive T cells bound the GR
antigen (Fig. 9). Indeed, in this experiment, most of the cells
binding the greatest amount of GR antigen were CD4 pos-
itive. GR antigen binding was also seen on CD8 positive T
cells in other experiments (data not shown). 
Comparison of the GR Antigen with P- and E-Selectin by SDS-
PAGE/Western Blot and Immunoprecipitation. Though the
distribution of the GR antigen is not consistent with either
P- (surface of activated platelets) or E-selectin (cytokine-
stimulated and/or proliferating endothelium only), most of
our understanding of the selectins have come from work
with human cells and it was possible that bovine P- or E-selec-
tin were simply different and that the GR antigen repre-
sented one or the other selectin. In Western blot analysis of
bovine platelet antigens, GR113 recognized a 110–120-kD
glycoprotein under nonreducing conditions (Fig. 10 A,
lane  1). In contrast, a polyclonal anti-bovine P-selectin an-
Figure 7. Effect of different inhibitors on GR staining of g/d T cells
treated with platelet supernatant fluid. Bovine lymphocytes were treated
with neuraminidase (0.1 mg/ml for 30 min at room temperature) or
O-sialoglycoprotease (50 mg/ml for 45 min at room temperature) before
the addition of supernatant fluid from thrombin-activated platelets, or
EDTA (2 mM), GR113 antibody, or negative control antibody was
added to the platelet supernatant fluid before addition to the bovine lym-
phocytes. After the treatments, the lymphocytes were washed, stained
with GR antibody, and flow cytometric analysis performed. The data are
presented as histograms. Expression is shown in arbitrary fluorescence
units on a log scale. A and B show the effects of an antibody negative control
and GR113, respectively. C and D show the effects of the buffer con-
trol and EDTA, respectively. E and F show the effects of the buffer
control and neuraminidase, respectively. G and H show the effects of the
buffer control and O-sialoglycoprotease, respectively. These experiments
are representative of at least two others showing the same result.
Figure 8. GR113 stains HECA 452 bright human lymphocytes. Hu-
man lymphocytes were treated with supernatant fluid from thrombin-
activated bovine platelets for 1.5 h, as described in Materials and Methods,
washed, and then analyzed by two-color flow cytometry using the
GR113 and HECA 452 mAb. A and B show the staining of the platelet
supernatant fluid treated cells in the absence or in the presence of the
blocking GR antibody, respectively. The quadrants reflect the upper level
of staining with a negative control antibody. These flow cytometric plots
are representative of at least three different experiments showing the same
result.1708 Leukocyte Rolling on 24 h-stimulated Endothelial Cells
tiserum recognized a band at 130 kD under reducing con-
ditions (Fig. 10 A, lane 3), exactly as previously reported
(30). The polyclonal anti–P-selectin antibody did not work
as well on nonreduced samples. In most instances the band
was very faint on the nonreduced gel (data not shown).
The latter observation may be related to the fact that the
polyclonal antiserum was raised against recombinant bovine
P-selectin expressed in E. coli and not the native protein
(30). GR113 did not react on reduced samples (data not
shown). To determine if the anti–P-selectin polyclonal an-
tibody reacted with reduced GR antigen, the GR antigen
was affinity purified as described (26), run on a SDS-PAGE
gel under nonreducing and reducing conditions, and probed
with GR113 or the anti–P-selectin antiserum, respectively.
As shown in Fig. 10 A, lanes 5 and 6, the anti–P-selectin
antiserum did not react with reduced, purified GR antigen.
We were particularly interested in determining the na-
ture of the GR antigen on the surface of activated endothe-
lial cells. To enhance getting E-selectin and the GR anti-
gen expressed on the cell surface at the same time for a
comparison, 6 h LPS-stimulated endothelial cells were sur-
face labeled with biotin. The labeled endothelial cells were
lysed in detergent and precipitated with polyclonal antise-
rum against either bovine E- or P-selectin, or with GR113.
A variable background band of 150 kD was detected with
specific antibody as well as preimmune serum controls (Fig.
10  B). GR113 specifically immunoprecipitated a surface
molecule from the endothelial cells of 110-120 kD (Fig. 10
B, lane 1, arrowhead). The E-selectin polyclonal antiserum
weakly immunoprecipitated a 90-kD glycoprotein (Fig. 10
B, lane 3, arrowhead), which was also seen in other experi-
ments using EL-246 (data not shown). In the experiment
shown in Fig. 10 B, the polyclonal anti–P-selectin antise-
rum immunoprecipitated a 130-kD molecule from the en-
dothelial cell lysates (lane 4, arrowhead); however, this result
was not repeated in four other experiments, thus the iden-
tity of that band could not be confirmed.
Discussion
Here, we report on the characterization of an adhesion
molecule (GR antigen) expressed by chronically stimulated
Figure 9. GR113 antigen binds to a subset of Con A expanded human
T cells expressing CD45RO, CD4, and CLA. Human lymphocytes were
cultured in Ex Vivo 15 medium, plus 5 mg/ml Con A for 6 d and then a
soluble GR113 antigen binding assay was done as described for Fig. 8.
Two-color analyses was done to compare the GR113 antigen binding
population with cells expressing CD4 and CD45RO, in addition to CLA,
as described in Materials and Methods. Controls represent background
due to second-stage alone and autofluorescence of the cell population.
Figure 10. SDS-PAGE/Western blot and immunoprecipitation analy-
sis of the platelet and endothelial cell GR antigen. In one experiment, bo-
vine platelets were lysed in detergent lysis buffer, run on an 8% PAGE gel,
transferred to nitrocellulose, and blotted with GR113 and a polyclonal
antiserum against bovine P-selectin. A shows the results. GR113 and neg-
ative control antibody are represented in lanes 1 and 2, which were run
under nonreducing conditions. Lanes 3 and 4 represent polyclonal antise-
rum against bovine P-selectin and preimmune control, respectively, on
samples run under reducing conditions. In another experiment, affinity
purified GR antigen was analyzed. Lanes 5 and 6 represent affinity-puri-
fied GR antigen run under nonreducing (lane 5) and reducing (lane 6) con-
ditions. GR113 was used to probe the nonreduced sample, whereas poly-
clonal anti–P-selectin was used to probe the reduced sample, as done in
lane 3. The results of the immunoprecipitation analysis of endothelial cells
are shown in B. Biotin-labeled endothelial cells were lysed in detergent
and antigens precipitated with polyclonal antiserum against either bovine
E-selectin or P-selectin, or with GR113. GR113, negative control, poly-
clonal antiserum against E-selectin, polyclonal antiserum against P-selec-
tin, and preimmune rabbit sera are shown in lanes 1–5, respectively. Ar-
row heads point to specific bands. The GR113 band has been repeated
.3 times and a similar size E-selectin band has been repeated with a mAb
against E-selectin. The P-selectin–specific band in the endothelial cell
analysis has not been clearly seen in five other experiments.1709 Jutila et al.
bovine endothelial cells in vitro and in vivo. The GR anti-
gen on endothelial cells supports myeloid cell rolling, as well
as the rolling of a subset of lymphocytes under flow condi-
tions. Platelets also produce the antigen, but very little is
expressed on their cell surface; whereas a functional form is
released upon activation of the platelet with thrombin or
PMA. The bovine antigen also has the capacity to bind hu-
man leukocytes. The binding activity of the GR antigen is
inhibited by EDTA and O-sialoglycoprotease treatment of
target leukocytes.
Though characteristics, such as inhibiton by EDTA and
support of leukocyte rolling, of the GR antigen are similar
to the known vascular selectins, E- and P-selectin, consid-
erable data suggests that the GR antigen is likely unique.
First, in precipitation studies the GR antigen is distinct from
the major forms of either P- or E-selectin. The GR antigen
has a molecular mass of 110–120 kD; whereas, bovine P- and
E-selectin have masses of 130 and 90–100 kD, respectively
(bovine selectins are slightly smaller than the homologues in
humans, because they contain fewer SCR domains [30–32]).
The GR antigen also exhibits other characteristics that dis-
tinguish it from known adhesion proteins. It is maintained
at optimal levels by endothelial cells from three different
tissues after 24 h stimulation in vitro, which distinguishes it
in most, but not all, instances from E- and P-selectin, but
not VCAM-1 (36–38). The GR antigen is also produced
by platelets, which is different from E-selectin and VCAM-1
(36, 38). GR113 mAb stains unactivated and activated
platelets equally well, a potential difference with P-selectin
(37). Inhibition of GR antigen binding to leukocytes by
O-sialoglycoprotease is another difference with the interac-
tion mediated by E-selectin (12, 13). Thrombin-activated
platelets release soluble GR antigen, which retains full func-
tional activity. Indeed, though antibody reactivity with un-
activated platelets can clearly be detected by flow cytometric
analysis, the expression levels are very low and the majority
of the platelet antigen appears to be internal and secreted.
P-selectin is a conventional transmembrane glycoprotein on
platelets (37), but it certainly could be released by damaged
platelets. GR antigen is also distinct from the recently de-
scribed VAP-1 endothelial cell adhesion molecule, which is
glycoprotein of 90 and 170 kD that mediates carbohydrate-
dependent binding of lymphocytes (39). Therefore, based
on its expression profiles, size, and functional activity, the
GR antigen is likely distinct from any other previously de-
fined adhesion molecule involved in leukocyte rolling in-
teractions under physiological flow. However, though the
data is quite compelling, we are still limited in the bovine
system with respect to available reagents, such as panels of
mAbs, to make definitive conclusions. Confirmation that
the GR antigen represents a new adhesion molecule (either
a previously described molecule with a new function or a
new molecule) or an alternate form of a known molecule,
such as P-selectin, will only be shown once its molecular
structure is determined.
Though the GR antigen has been defined in the bovine
system, evidence points to the existence of a similar mole-
cule in humans. GR113 mAb does not crossreact with hu-
man cells; however, the GR antigen has the capacity to
bind human myeloid cells and a subset of lymphocytes, the
same pattern as defined with bovine leukocytes. The bind-
ing of the antigen to the human cells is blocked by EDTA
and GR113, demonstrating that it is a specific interaction.
Interestingly, lymphocytes taken directly from the blood and
expressing the highest levels of CLA, an antigen associated
with E-selectin binding (13, 27), bind the GR antigen. CLA
is expressed by CD45RO positive T cells (memory cells). In
preliminary experiments, we found that GR antigen bound
a subset of Con A expanded lymphocytes, which homo-
genously expressed CD45RO, indicting that expression of
this suface antigen does not correlate precisely with GR anti-
gen binding. GR antigen is bound by both CD4 and CD8
human T cells.
The intent of this study was not the characterization of
the counter-receptor for the GR antigen, but certain in-
sights have been gained. First and foremost, though CLA
bright cells bind the GR antigen and cells from some donors
show a linear correlation between CLA expression and GR
antigen binding, CLA is not a prerequisite nor sufficient for
binding. CLA is a carbohydrate moiety associated with
E-selectin binding expressed on a variety of different glyco-
proteins (13, 27, 40, 41). Neuraminidase treatment (0.1 U/ml
for 30 min) of bovine g/d T cells or human lymphocytes
does not block binding of soluble GR antigen, though HECA
452 reactivity is greatly reduced on the human cells. O-sialo-
glycoprotease treatment of leukocytes effectively blocks their
ability to bind the GR antigen, suggesting that the ligand for
the GR antigen is a mucin. O-sialoglycoprotease has no ef-
fect on CLA (13). In contrast, at least one of the counter-
receptors for the GR antigen likely is similar if not identical
to the P-selectin ligand on leukocytes, P-selectin glycopro-
tein ligand-1 (PSGL-1) (42, 43). O-sialoglycoprotease treat-
ment of leukocytes blocks their ability to bind P-selectin,
by cleaving PSGL-1 (44, 45).
Our functional studies point to a potential role for the
GR antigen in directing leukocytes to sites of chronic in-
flammation. We have found from in vivo antibody block-
ing studies that inhibition of L- and E-selectin, though
quite effective in blocking acute (,6 h) inflammatory events,
is not as effective in calves in blocking chronic inflamma-
tion, such as that associated with DTH reactions (24 and 48 h)
(Jutila, M.A., unpublished observations). The limited chronic
inflammatory lesions examined in this report have many ves-
sels that express high levels of the GR antigen. Indeed, there
is a striking correlation between the expression of the GR
antigen and the site of leukocyte infiltration into a chronic
lesion induced by potassium permanganate. A few scattered
GR antigen positive venules can be found in uninflamed
skin and expression can be increased by treatment with LPS
for 4–6 h, but the level of endothelial cell expression of
GR antigen at this early timepoint is far less than the level
of E-selectin expression. We have been unable to detect
E-selectin positive vessels in the potassium permanganate
lesion. From these initial studies, we predict that the GR
antigen has a minimal role early in inflammation, but may
have a major contribution in sites of chronic inflammation,1710 Leukocyte Rolling on 24 h-stimulated Endothelial Cells
complementing the role of VCAM-1, E-selectin, VAP-1,
or other adhesion proteins. Currently, a greater survey of
inflamed tissues is being studied to identify relevant in vivo
settings to examine the functional importance of the GR
antigen in the animal.
The function of the GR antigen in supporting adhesion
appears restricted to the endothelium, even though the an-
tigen is also produced by platelets. The low level expression
of the GR antigen on the surface of platelets does not sup-
port leukocyte rolling. The platelet antigen is released in a
soluble and functional form following stimulation of the
cell with thrombin or PMA. The soluble platelet antigen is
quite effective in binding to leukocytes, which suggest a pos-
sible function in down regulating leukocyte endothelial cell
interactions during the course of overt inflammation. It may
be that as platelets accumulate at sites of vessel damage, this
dampens the leukocyte inflammatory response through re-
lease of the GR antigen from intracellular stores. If true,
this would represent another mode of regulation of inflam-
mation.
In summary, from functional studies with human and
now bovine cells, evidence supports the existence of a po-
tentially new adhesion molecule that mediates leukocyte
rolling under flow conditions on chronically stimulated en-
dothelial cells. To date, the identification of this new mole-
cule has not been reported. Here we provide the initial
characterization of an endothelial cell transmembrane and
soluble platelet molecule that may represent this undefined
adhesion protein (a new molecule or a previously charac-
terized molecule with a new function). Molecular charac-
terization of the bovine molecule as well as identification of
the human homologue may result in the identification of a
new adhesion system that can be exploited in the develop-
ment of novel antiinflammatory therapies.
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